These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 21062268)

  • 1. Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism.
    Patel U; Mark NM; Machler BC; Levine VJ
    Br J Dermatol; 2011 Mar; 164(3):670-2. PubMed ID: 21062268
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of recalcitrant skin ulcers as a side-effect of treatment with topical 5% imiquimod cream: report of two cases.
    Kalampalikis A; Goetze S; Elsner P
    J Eur Acad Dermatol Venereol; 2014 Nov; 28(11):1574-6. PubMed ID: 24456017
    [No Abstract]   [Full Text] [Related]  

  • 3. Imiquimod reactivation of lichen planus.
    Domingues E; Chaney KC; Scharf MJ; Wiss K
    Cutis; 2012 Jun; 89(6):276-7, 283. PubMed ID: 22838091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of imiquimod-induced alopecia.
    Conde J; Davis K; Ntuen E; Balmer N; Jones D; McMichael A
    J Dermatolog Treat; 2010 Mar; 21(2):122-4. PubMed ID: 19488918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histologic features mimicking mycosis fungoides induced by imiquimod, 5%: a potential pitfall for dermatopathologists.
    Altamura D; Simonacci F; Hirbod T; Arkoumani E; Verdolini R
    JAMA Dermatol; 2014 Nov; 150(11):1236-7. PubMed ID: 25133432
    [No Abstract]   [Full Text] [Related]  

  • 6. Development of subacute cutaneous lupus erythematosus associated with the use of imiquimod to treat actinic keratoses.
    Burnett TJ; English JC; Ferris LK
    J Drugs Dermatol; 2010 Aug; 9(8):1022-4. PubMed ID: 20684157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythema multiforme as a reaction to imiquimod 5% cream.
    Yanes DA; Kaffenberger JA; Carr DR
    Dermatol Online J; 2017 Feb; 23(2):. PubMed ID: 28329504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial.
    Gebauer K; Shumack S; Cowen PS
    Br J Dermatol; 2009 Oct; 161(4):897-903. PubMed ID: 19545297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.
    Quist SR; Gollnick HP
    Expert Opin Pharmacother; 2011 Feb; 12(3):451-61. PubMed ID: 21254950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis.
    Kose O; Koc E; Erbil AH; Caliskan E; Kurumlu Z
    J Dermatolog Treat; 2008; 19(3):159-63. PubMed ID: 18569272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imiquimod 5% cream for actinic keratosis.
    Perras C
    Issues Emerg Health Technol; 2004 Sep; (61):1-4. PubMed ID: 15382379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the back of the hands to apply imiquimod.
    Hogan K; Cullan J; Isedeh P; Aires D
    J Am Acad Dermatol; 2016 Jan; 74(1):e17. PubMed ID: 26702809
    [No Abstract]   [Full Text] [Related]  

  • 13. Zyclara (imiquimod) cream, 3.75%.
    Gupta AK; Cooper EA; Abramovits W
    Skinmed; 2010; 8(4):227-9. PubMed ID: 21137610
    [No Abstract]   [Full Text] [Related]  

  • 14. Topical Imiquimod in the Treatment of Conjunctival Actinic Keratosis.
    Rowlands MA; Giacometti JN; Servat J; Materin MA; Levin F
    Ophthalmic Plast Reconstr Surg; 2017; 33(1):e21-e23. PubMed ID: 25853505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2013 Nov; 12(11):1278-82. PubMed ID: 24196337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the effects of topical treatment of calcipotriol, camptothecin, clobetasol and tazarotene on an imiquimod-induced psoriasis-like mouse model.
    Sun J; Dou W; Zhao Y; Hu J
    Immunopharmacol Immunotoxicol; 2014 Feb; 36(1):17-24. PubMed ID: 24286371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience of imiquimod 3.75% for actinic keratosis: results from a case series.
    Tambone S; Fargnoli MC; Capizzi R; Peris K
    G Ital Dermatol Venereol; 2018 Jun; 153(3):333-337. PubMed ID: 26439591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imiquimod 5% cream for the treatment of actinic keratoses.
    Somani N; Rivers JK
    Skin Therapy Lett; 2005 Mar; 10(2):1-6. PubMed ID: 15986078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials.
    Lebwohl M; Dinehart S; Whiting D; Lee PK; Tawfik N; Jorizzo J; Lee JH; Fox TL
    J Am Acad Dermatol; 2004 May; 50(5):714-21. PubMed ID: 15097955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recruitment of plasmacytoid dendritic cells to skin regulates treatment responsiveness of actinic keratosis to imiquimod.
    Ogawa Y; Kawamura T; Matsuzawa T; Aoki R; Shimada S
    J Dermatol Sci; 2014 Oct; 76(1):67-9. PubMed ID: 25088809
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.